

17.06.2019

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building,
Phirozejeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Scrip Code : 524742

By BSE Listing

National Stock Exchange of India Ltd.,
Department of Corporate Services,
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051.
Scrip Code : CAPLIPOINT

By NEAPS

Dear Sirs,

SUB:PRESS RELEASE – DISCLOSURE UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS,2015.

Please find the enclosed copy of Press Release being published today.

Kindly take the same on your records.

Thanking you,

Yours Faithfully,
For Caplin Point Laboratories Limited


Company Secretary
Enclosure : As Above



PRESS RELEASE

US FDA INSPECTION COMPLETED AT CAPLIN STERILES INJECTABLE SITE

Chennai, June 17, 2019: Caplin Steriles Limited, a Wholly Owned Subsidiary Company of Caplin Point Laboratories Limited, announces that US FDA has completed inspection of its Sterile Injectable site at Gummidipoondi between June 6th and 14th, 2019. At the end of this scheduled GMP inspection, there were only two observations. The Company believes these to be of procedural in nature and the corrective and preventive actions for these observations will be presented to the US FDA shortly. The observations made were not repeat observations or related to data integrity.

This was the third US FDA audit at the plant since 2016. Mr C.C.Paarthipan, Chairman of Caplin Point Laboratories Limited commented "Our primary focus is to ensure integrity and maintain transparency in our quality systems, and we're pleased with the result of yet another successful audit."

ABOUT CAPLIN STERILES LTD

Caplin Steriles Ltd, a Wholly Owned Subsidiary Company of Caplin Point Laboratories Limited, is a niche sterile product manufacturing company that is approved by US FDA and EU-GMP. The company has filed 11 ANDAs so far, with 4 approvals. The company has a larger pipeline of 40+ ANDAs that it intends to file over the next 5 years.

ABOUT CAPLIN POINT LABORATORIES LTD

Caplin Point Laboratories Limited is a fast growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point Laboratories Limited has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company has also entered regulated markets such as US through its Wholly Owned Subsidiary Caplin Steriles Limited,

Caplin Point has been selected on Forbes Asia's "200 Best Under a Billion" list for three consecutive years (2014, 2015 & 2016), and was recently awarded "The Emerging Company of 2018" by Economic Times Family Business Awards.





CAUTIONARY STATEMENT:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

Investor Relations Team at Caplin

Mr. Vinod Kumar (Company Secretary)

Tel: +91 44 24968000

investor@caplinpoint.net

Dikshita Jain

Christensen Investor Relations

Tel : +91 22 4215 0210

djain@christensenir.com

Registered Office

Narbhavi No. 3, Lakshmanan Street,
T Nagar, Chennai, Tamil Nadu,
600017

Telephone: 044-28156653

CIN: L24231TN1990PLC019053

ISIN: INE475E01026

NSE Code: CAPLIPOINT

BSE CODE: 524742

Website: www.caplinpoint.net

